Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
meningococcal conjugate vaccine GSK 134612
- Development stage
- Approved
- Lead developer
- GSK
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
A **quadrivalent meningococcal conjugate vaccine** targeting Neisseria meningitidis serogroups A, C, W-135, and Y, developed by GSK. This vaccine uses polysaccharides from these serogroups conjugated to a carrier protein (typically tetanus toxoid, TT). It is designed to induce immunogenicity by stimulating an immune response that generates antibodies to protect against invasive meningococcal disease. The vaccine is administered intramuscularly and is intended for immunization of infants, children, adolescents, and adults. The vaccine shows well-tolerated safety profiles and persistent antibody responses across age groups[1][3][4][5][6][7][8].
- Brand names
- Nimenrix
- Other names
- MenACWY - GlaxoSmithKlineMenACWY conjugated vaccine - GlaxoSmithKline
02
Targets
NmA CPS (Neisseria meningitidis group A capsular polysaccharide)Group Y CPS (Neisseria meningitidis group Y capsular polysaccharide)Neisseria meningitidis group C capsular polysaccharideMenW CPS (Neisseria meningitidis serogroup W capsular polysaccharide)TT (Tetanus toxoid)
Beyond the preview
Go deeper on meningococcal conjugate vaccine GSK 134612.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on meningococcal conjugate vaccine GSK 134612.